VTRO (Vitro Biopharma) EBIT: $-6.66 Mil (TTM As of Oct. 2022)


What is Vitro Biopharma EBIT?

Vitro Biopharma VTRO EBIT is $-6.66 Mil as of Oct. 2022. The stock has 6 warning signs investors should review.

Vitro Biopharma's earnings before interest and taxes (EBIT) for the three months ended in Oct. 2022 was $-6.66 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Oct. 2022 was $-6.66 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Vitro Biopharma's annualized ROC % for the quarter that ended in Oct. 2022 was -297.99%. Vitro Biopharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Oct. 2022 was -4,948.56%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Vitro Biopharma  (AMEX:VTRO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Vitro Biopharma's annualized ROC % for the quarter that ended in Oct. 2022 is calculated as:

ROC % (Q: Oct. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Oct. 2021 ) + Invested Capital (Q: Oct. 2022 ))/ count )
=-20.208 * ( 1 - 0% )/( (7.162 + 6.401)/ 2 )
=-20.208/6.7815
=-297.99 %

where

Invested Capital(Q: Oct. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11.129 - 0.754 - ( 3.627 - max(0, 1.423 - 4.636+3.627))
=7.162

Invested Capital(Q: Oct. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8.574 - 1.777 - ( 0.742 - max(0, 2.54 - 2.936+0.742))
=6.401

Note: The Operating Income data used here is four times the quarterly (Oct. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Vitro Biopharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Oct. 2022 is calculated as:

ROC (Joel Greenblatt) %(Q: Oct. 2022 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Oct. 2021  Q: Oct. 2022
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-26.648/( ( (0.448 + max(-0.244, 0)) + (0.629 + max(-0.233, 0)) )/ 2 )
=-26.648/( ( 0.448 + 0.629 )/ 2 )
=-26.648/0.5385
=-4,948.56 %

where Working Capital is:

Working Capital(Q: Oct. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.127 + 0.118 + 0.764) - (0.754 + 0.5 + -0.00099999999999989)
=-0.244

Working Capital(Q: Oct. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.074 + 0.28 + 1.84) - (1.777 + 0.65 + 0)
=-0.233

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Oct. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Vitro Biopharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Oct. 2022 )
=-6.662/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitro Biopharma EBIT Related Terms

Vitro Biopharma EBIT Historical Data

* Premium members only.

The historical data trend for Vitro Biopharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitro Biopharma EBIT Chart

Vitro Biopharma Annual Data
Trend Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15 Oct17 Oct21 Oct22
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.17 -0.16 -0.30 -4.12 -6.66

Vitro Biopharma Quarterly Data
Oct00 Oct01 Oct02 Oct03 Oct04 Oct05 Oct06 Oct07 Oct08 Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15 Oct17 Oct21 Oct22
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.17 -0.16 -0.30 -4.12 -6.66

VTRO vs : EBIT Comparison

For the Biotechnology subindustry, Vitro Biopharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vitro Biopharma EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vitro Biopharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vitro Biopharma's EV-to-EBIT falls into.


Vitro Biopharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Oct. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-6.66 Mil mean?
Vitro Biopharma (VTRO) has a EBIT of $-6.66 Mil as of Oct. 2022. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Vitro Biopharma.
Is Vitro Biopharma's EBIT too high?
Vitro Biopharma's current EBIT is $-6.66 Mil.
How does Vitro Biopharma's EBIT compare to ?
Vitro Biopharma's EBIT of $-6.66 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Vitro Biopharma. Vitro Biopharma's current EBIT is $-6.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitro Biopharma stock overvalued right now?
Vitro Biopharma (VTRO) has a current EBIT of $-6.66 Mil. The current EBIT is $-6.66 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Vitro Biopharma (VTRO), the current EBIT is $-6.66 Mil as of Oct. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vitro Biopharma Business Description

Comparable Companies
Address 4621 Technology Drive, Golden, CO, USA, 80403
Vitro Diagnostics Inc is a US-based company, which is dedicated to providing high-quality commercialized cell lines, media, and stem cell technology for applications in stem cell research, drug discovery, and therapies. In addition, it also provides tools for clinical development focused on Mesenchymal Stem Cells (MSCs). Further, it offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells. Geographically business activities are functioned through the region of United States.